A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06852231 Administered To Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06852231 Administered To Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs PF-06852231 (Primary)
  • Indications Neurological disorders
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Feb 2018 Status changed from recruiting to completed.
    • 16 Jan 2018 Planned End Date changed from 8 Mar 2018 to 1 Feb 2018.
    • 16 Jan 2018 Planned primary completion date changed from 8 Mar 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top